Studying CpG1018 for Early Alzheimer's Disease
This study is testing a drug called CpG1018 in people with mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's dementia. CpG1018 is given as a shot under the skin. Researchers want to see if CpG1018 is safe and how well people tolerate it. You might be able to join if you are 60 to 85 years old, have MCI or mild Alzheimer's, and have a positive amyloid PET scan (a brain scan that looks for signs of Alzheimer's). The study will measure side effects and check for certain markers in your blood. The current status of this study is unclear.
- Study design
- This is a double-blind, placebo-controlled study, meaning neither you nor your doctor will know if you are receiving the study drug or a placebo (an inactive substance). It plans to include 39 participants across three different dose levels.
- What's involved
- You would receive subcutaneous injections (shots under the skin) of either CpG1018 or a placebo for 8 weeks. Safety will be monitored for up to 18 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored for up to 18 weeks after starting the study treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Innate Immunity Stimulation Via TLR9 in Early AD
At a glance
Conditions
NCT05606341
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
NYU Langone Health
New York, New Yorkno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Arjun Masurkar, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Patient-Reported Adverse Events (AEs)Up to Week 18
AEs defined as any symptom, sign, illness or experience that develops or worsens in severity during the course of the study.
- Percentage of Participants with Rheumatoid Factor (RF) Confirmed by Autoimmunity Marker Screening Test ResultUp to Week 18
Evaluation of RF in patient blood samples at Baseline, Day 56, Week 14 and Week 18.
- Percentage of Participants with Antinuclear Antibody (ANA) Confirmed by Autoimmunity Marker Screening Test ResultUp to Week 18
Evaluation of ANA in patient blood samples at Baseline, Day 56, Week 14 and Week 18.
- Percentage of Participants with Antineutrophil Cytoplasmic Antibody (ANCA) Confirmed by Autoimmunity Marker Screening Test ResultUp to Week 18
Evaluation of ANCA in patient blood samples at Baseline, Day 56, Week 14 and Week 18.
- Percentage of Participants with Amyloid-Related Imaging Abnormalities-Haemosiderin (ARIA-H) Confirmed by Magnetic Resonance Imaging (MRI)Up to Week 14
Evaluation of ARIA-H at Baseline and Week 14 using 3T PET/MR Siemens Biograph system.
- Percentage of Participants with Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by Magnetic Resonance Imaging (MRI)Up to Week 14
Evaluation of ARIA-E at Baseline and Week 14 using 3T PET/MR Siemens Biograph system.